People

Kevin Krause

ArrePath president, CEO and board member. Previously chief strategy officer at AN2 Therapeutics, with drug development and corporate development experience at Achaogen, Cerexa and Theravance BioPharma. Holds an MBA from UC Berkeley and a BS in cell and molecular biology from San Francisco State.